Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s Mekinist/Tafinlar Combo Pushes The Price Bar

This article was originally published in The Pink Sheet Daily

Executive Summary

GSK’s MEK inhibitor Mekinist and BRAF inhibitor Tafinlar are the first two targeted therapies approved in combination for the treatment of metastatic melanoma. The prices of the separate components are below other comparable oncology launches, but the combination will push the price to over $17,115 for a month of treatment.

Advertisement

Related Content

The Magnitude Matters: GSK Approvals Show How To Use PFS After Other Drugs Show Survival
GSK Prices Tafinlar At $7,600/month, Undercutting Roche’s Zelboraf
The Next Wave For Melanoma

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076490

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel